化合物LNP023 hydrochloride T9189
面议
- TargetMol
- 生产商
- 进口
- 美国
- 现货
- 全国
- 7
- 0
Product IntroductionBioactivity英文名: Iptacopan hydrochloride描述: Iptacopan hydrochloride (LNP023 hydrochloride) 是一种可口服、高效和高
AI问答
配套的仪器设备？
可以搭配的相关耗材试剂？
耗材描述
Product Introduction
Bioactivity
英文名: Iptacopan hydrochloride
描述: Iptacopan hydrochloride (LNP023 hydrochloride) 是一种可口服、高效和高选择性的因子 B 抑制剂，IC50 为 10 nM。 LNP023 显示与人因子 B 的直接、可逆和高亲和力结合，KD 为 7.9 nM。
体外活性: LNP023 demonstrates excellent selectivity over other proteases affording IC50 values of >30 μM across a panel of 41 human proteases, including the AP protein factor D (>100 μM)[3].
体内活性: LNP023 (20-180 mg/kg; oral administration) is effective upon prophylactic and therapeutic dosing in an experimental model of membranous nephropathy in rats and prevents KRN (150 μL)-induced arthritis in mice[2].After oral administration (rat 30 and, dog 10 mg/kg), LNP023 exhibits moderate half-lives (T1/2; Wistar Han rats 3.4 h, beagle dogs 5.5 h) and Cmax (Wistar Han rats 410 nM, beagle dogs 2200 nM)[3].
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: H2O : 50 mg/mL (108.94 mM)
DMSO : 50 mg/mL (108.94 mM)
关键字: LNP 023 | hemoglobinuria | inhibit | PNH | Iptacopan hydrochloride | atypical | pathogenesis | Inhibitor | LNP023 | factor B | system | LNP 023 Hydrochloride | Iptacopan | Complement System | complement | paroxysmal | syndrome | LNP-023 | pathway | LNP-023 Hydrochloride | hemolytic | uremic | alternative | LNP023 Hydrochloride | nocturnal | Iptacopan Hydrochloride
相关产品: Lipoteichoic acid | Complement factor D-IN-2 | C3a 70-77 2TFA(63555-63-5(free base)) | ADH-503 | 3-Phenoxybenzaldehyde | CP-447697 | NDT 9513727 | JR14a | Danicopan | Avacopan
相关库: Drug Repurposing Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Inhibitor Library | Highly Selective Inhibitor Library | Orally Active Compound Library | NO PAINS Compound Library | Bioactive Compound Library
Bioactivity
英文名: Iptacopan hydrochloride
描述: Iptacopan hydrochloride (LNP023 hydrochloride) 是一种可口服、高效和高选择性的因子 B 抑制剂，IC50 为 10 nM。 LNP023 显示与人因子 B 的直接、可逆和高亲和力结合，KD 为 7.9 nM。
体外活性: LNP023 demonstrates excellent selectivity over other proteases affording IC50 values of >30 μM across a panel of 41 human proteases, including the AP protein factor D (>100 μM)[3].
体内活性: LNP023 (20-180 mg/kg; oral administration) is effective upon prophylactic and therapeutic dosing in an experimental model of membranous nephropathy in rats and prevents KRN (150 μL)-induced arthritis in mice[2].After oral administration (rat 30 and, dog 10 mg/kg), LNP023 exhibits moderate half-lives (T1/2; Wistar Han rats 3.4 h, beagle dogs 5.5 h) and Cmax (Wistar Han rats 410 nM, beagle dogs 2200 nM)[3].
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: H2O : 50 mg/mL (108.94 mM)
DMSO : 50 mg/mL (108.94 mM)
关键字: LNP 023 | hemoglobinuria | inhibit | PNH | Iptacopan hydrochloride | atypical | pathogenesis | Inhibitor | LNP023 | factor B | system | LNP 023 Hydrochloride | Iptacopan | Complement System | complement | paroxysmal | syndrome | LNP-023 | pathway | LNP-023 Hydrochloride | hemolytic | uremic | alternative | LNP023 Hydrochloride | nocturnal | Iptacopan Hydrochloride
相关产品: Lipoteichoic acid | Complement factor D-IN-2 | C3a 70-77 2TFA(63555-63-5(free base)) | ADH-503 | 3-Phenoxybenzaldehyde | CP-447697 | NDT 9513727 | JR14a | Danicopan | Avacopan
相关库: Drug Repurposing Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Inhibitor Library | Highly Selective Inhibitor Library | Orally Active Compound Library | NO PAINS Compound Library | Bioactive Compound Library
猜你喜欢
感兴趣产品